However, the company reported an 8 percent decrease in net income to $18.3 million. The company’s president and CEO Brian Concannon said the company is still recovering from the OrthoPAT recall and continues to resolve its quality issues. The company’s plasma and blood management solutions business lines experienced growth during this period.
Related Articles on Orthopedic Devices:
NuVasive Shares Rise After Judge’s Ruling
Zimmer’s 2.9% Sales Increase Driven by Foreign Markets
Interventional Spine Receives FDA Clearance for Spine Device
OrthoPAT Recall Still Hurts Haemonetics 3Q Financial Report
Medical device company Haemonetics reported a third quarter net revenue of $191.2 million, an 8 percent increase over the same period last year, according to a company news release.
RCM Tech Trends You Can’t Ignore: Fresh Insights from UC San Diego Health
Recommended Live Webinar on Feb 11, 2026 12:00 PM - 1:00 PM CST